• Dorottya Laczkó, Michael J Hogan, Sushila A Toulmin, Philip Hicks, Katlyn Lederer, Brian T Gaudette, Diana Castaño, Fatima Amanat, Hiromi Muramatsu, Thomas H Oguin, Amrita Ojha, Lizhou Zhang, Zekun Mu, Robert Parks, Tomaz B Manzoni, Brianne Roper, Shirin Strohmeier, István Tombácz, Leslee Arwood, Raffael Nachbagauer, Katalin Karikó, Jack Greenhouse, Laurent Pessaint, Maciel Porto, Tammy Putman-Taylor, Amanda Strasbaugh, Tracey-Ann Campbell, Paulo J C Lin, Ying K Tam, Gregory D Sempowski, Michael Farzan, Hyeryun Choe, Kevin O Saunders, Barton F Haynes, Hanne Andersen, Laurence C Eisenlohr, Drew Weissman, Florian Krammer, Paul Bates, David Allman, Michela Locci, and Norbert Pardi.
• Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
• Immunity. 2020 Oct 13; 53 (4): 724-732.e7.

AbstractSARS-CoV-2 infection has emerged as a serious global pandemic. Because of the high transmissibility of the virus and the high rate of morbidity and mortality associated with COVID-19, developing effective and safe vaccines is a top research priority. Here, we provide a detailed evaluation of the immunogenicity of lipid nanoparticle-encapsulated, nucleoside-modified mRNA (mRNA-LNP) vaccines encoding the full-length SARS-CoV-2 spike protein or the spike receptor binding domain in mice. We demonstrate that a single dose of these vaccines induces strong type 1 CD4+ and CD8+ T cell responses, as well as long-lived plasma and memory B cell responses. Additionally, we detect robust and sustained neutralizing antibody responses and the antibodies elicited by nucleoside-modified mRNA vaccines do not show antibody-dependent enhancement of infection in vitro. Our findings suggest that the nucleoside-modified mRNA-LNP vaccine platform can induce robust immune responses and is a promising candidate to combat COVID-19.Published by Elsevier Inc.

72 keywords...

hide…